Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lansoprazole, quantity: 30 mg - capsule - excipient ingredients: colloidal anhydrous silica; macrogol 300; gelatin; indigo carmine; carmoisine; maize starch; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; hypromellose; sucrose; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - adults:. lanzopran capsules are indicated for. - healing and long-term management of reflux oesophagitis. . - healing and long-term management for patients with duodenal ulcer.. - healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . - patients with benign peptic lesions that do not respond to h2-receptor antagonists.. - eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics. . - relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric and adolescent patients i to 17 years of age:. lanzopran capsules are indicated for. - treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . - healing of erosive oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lansoprazole, quantity: 15 mg - capsule - excipient ingredients: macrogol 300; iron oxide yellow; hypromellose; purified talc; maize starch; sucrose; titanium dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); colloidal anhydrous silica; quinoline yellow; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - adults:. lanzopran capsules are indicated for. - healing and long-term management of reflux oesophagitis. . - healing and long-term management for patients with duodenal ulcer.. - healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . - patients with benign peptic lesions that do not respond to h2-receptor antagonists.. - eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics. . - relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric and adolescent patients i to 17 years of age:. lanzopran capsules are indicated for. - treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . - healing of erosive oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lansoprazole, quantity: 15 mg - capsule - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); iron oxide yellow; sucrose; colloidal anhydrous silica; macrogol 300; titanium dioxide; gelatin; purified talc; maize starch; quinoline yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - adults:. lanzopran capsules are indicated for. - healing and long-term management of reflux oesophagitis. . - healing and long-term management for patients with duodenal ulcer.. - healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . - patients with benign peptic lesions that do not respond to h2-receptor antagonists.. - eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics. . - relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric and adolescent patients i to 17 years of age:. lanzopran capsules are indicated for. - treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . - healing of erosive oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 5 mg - capsule, modified release - excipient ingredients: lactose monohydrate; titanium dioxide; hypromellose; sodium lauryl sulfate; iron oxide red; magnesium stearate; iron oxide yellow; ethylcellulose; gelatin; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf-xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 1 mg - capsule, modified release - excipient ingredients: hypromellose; iron oxide yellow; gelatin; sodium lauryl sulfate; titanium dioxide; ethylcellulose; iron oxide red; magnesium stearate; lactose monohydrate; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf-xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 0.5 mg - capsule, modified release - excipient ingredients: iron oxide yellow; hypromellose; iron oxide red; titanium dioxide; lactose monohydrate; ethylcellulose; magnesium stearate; sodium lauryl sulfate; gelatin; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf-xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tacrolimus monohydrate, quantity: 5.11 mg (equivalent: tacrolimus, qty 5 mg) - capsule, hard - excipient ingredients: hypromellose; magnesium stearate; croscarmellose sodium; lactose monohydrate; shellac; ethanol absolute; isopropyl alcohol; butan-1-ol; propylene glycol; strong ammonia solution; iron oxide black; potassium hydroxide; purified water; titanium dioxide; sorbitan monolaurate; iron oxide red; potable water; gelatin; sodium lauryl sulfate - adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tacrolimus monohydrate, quantity: 1.022 mg (equivalent: tacrolimus, qty 1 mg) - capsule, hard - excipient ingredients: hypromellose; lactose monohydrate; croscarmellose sodium; magnesium stearate; shellac; isopropyl alcohol; ethanol absolute; butan-1-ol; propylene glycol; strong ammonia solution; iron oxide black; potassium hydroxide; purified water; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; potable water; gelatin; sodium lauryl sulfate - adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tacrolimus monohydrate, quantity: 0.511 mg (equivalent: tacrolimus, qty 0.5 mg) - capsule, hard - excipient ingredients: hypromellose; lactose monohydrate; croscarmellose sodium; magnesium stearate; shellac; isopropyl alcohol; ethanol absolute; butan-1-ol; propylene glycol; strong ammonia solution; iron oxide black; potassium hydroxide; purified water; titanium dioxide; iron oxide yellow; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: butylated hydroxyanisole; iron oxide red; purified water; gelatin; iron oxide yellow; fractionated coconut oil; glycerol; sorbitol solution (70 per cent) (non-crystallising); butylated hydroxytoluene - calciprox is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. calciprox is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. calciprox is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.